Profile picture of Francis Parnis

Dr Francis Parnis

MBBS, FRACP
Medical Oncologist
Become a Patient

Dr Francis Parnis is committed to supporting his patients every step of the way. He delivers prompt, personalised treatment plans for those in his care, ensuring South Australian patients have access to the latest clinical research and trials.

Biography

Dr Francis Parnis is an experienced medical oncologist at Icon Cancer Centre Adelaide. In 1985 he graduated from the University of Adelaide with a Bachelor of Medicine, Bachelor of Surgery (MBBS) before practicing as a medical oncologist at the Queen Elizabeth, Flinders Medical Centre, Royal Adelaide, Queen Mary’s Hospital Kent and Guys Hospital in London.

In 1995 he co-founded Adelaide Cancer Centre, now known as Icon Cancer Centre Adelaide, with A/Prof Dusan Kotasek. Over the past 25 years, the centre has grown into the largest private oncology facility in South Australia. His clinical experience covers a broad range of solid tumour malignancies with special clinical interest in clinical research, clinical trials, gastrointestinal cancer, genitourinary cancer and prostate cancer.

Affiliations & Memberships

  • Private Cancer Physicians of Australia (PCPA)
  • Royal Australasian College of Physicians (RACP)

Special Interests

Dr Francis Parnis accepts referrals for all cancer types, with a special clinical interest in:
  • Clinical research
  • Gastrointestinal cancer
  • Genitourinary cancer
  • Prostate cancer

Icon Locations

Adelaide (Kurralta Park) View centre

Visiting Locations

  • St Andrew’s Medical Centre

Publications

  • Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease. A. Schmidt, A. Anton, J. Shapiro, S. Wong, A. Azad, E. Kwan, L. Spain, A. Muthusamy, J. Torres, P. Parente, F. Parnis, J. Goh, A. Joshua, D. Pook, P. Gibbs, B. Tran & A. Weickhardt. Asia-Pacific Journal of Clinical Oncology, 2020.

  • Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials. C.L. Gan, S. Dudani, C. Wells, Z. Bakouny, N. Dizman, S. Nazli, S. Pal, B. Szabados, L. Wood, C. Kollmannsberger, N. Agarwal, F. Donskov, N. Basappa, G. Bjarnason, F. Parnis, C. Porta, I. Davis, U. Vaishampayan, R. Kanesvaran, T. Choueiri & D. Heng. Journal of Clinical Oncology, 2020; 38(15_suppl): 5070.

  • Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. T. Beer, E. Kwon, C. Drake, K. Fizazi, C. Logothetis, G. Gravis, V. Ganju, J. Polikoff, F. Saad, P. Humanski, J. Piulats, P. Gonzalez Mella, S. Ng, D. Jaeger, F. Parnis, F. Franke, J. Puente, R. Carvajal, L. Sengelov, W. Gerritsen. Journal of Clinical Oncology, 2016; 35(1).

  • A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) +/- nab-paclitaxel in patients with pancreatic cancer. Hidalgo, P. Cooray, A. Carrato, M. Jameson, F. Parnis, M. Jeffery, P. Grimison, R. Stagg, E. Holmgren, A. Kapoun, J. Dupont & N. Tebbutt. Journal of Clinical Oncology, 2016; 34(4_suppl): 341.

  • Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer. P. Parente, F. Parnis & H. Gurney. Asia-Pacific Journal of Clinical Oncology, 2014; 10(3).

View all

Search